ArticleThe Journal of surgical research2007
A bioartificial liver device secreting interleukin-1 receptor antagonist for the treatment of hepatic failure in rats.
Article in The Journal of surgical research, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 27 citations in OpenAlex.
- Interleukin-1 Family Cytokines: Keystones in Liver Inflammatory Diseases.Frontiers in immunology · 2019Review
- Hepatitis B virus X protein induces hepatic stem cell-like features in hepatocellular carcinoma by activating KDM5B.World journal of gastroenterology · 2017Article
- Interleukin-1α and Interleukin-1β play a central role in the pathogenesis of fulminant hepatic failure in mice.PloS one · 2017Article
- Inhibition of microRNA-214 ameliorates hepatic fibrosis and tumor incidence in platelet-derived growth factor C transgenic mice.Cancer science · 2015Article
- Microengineered cell and tissue systems for drug screening and toxicology applications: Evolution ofTechnology · 2015Article
- IL-1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in mice.The Journal of clinical investigation · 2012Review
- Type I interferons protect from Toll-like receptor 9-associated liver injury and regulate IL-1 receptor antagonist in mice.Gastroenterology · 2011Article
- Interleukin-1 receptor antagonist modulates the early phase of liver regeneration after partial hepatectomy in mice.PloS one · 2011Article
- Long-term superior performance of a stem cell/hepatocyte device for the treatment of acute liver failure.Tissue engineering. Part A · 2009Article
- An overview of animal models for investigating the pathogenesis and therapeutic strategies in acute hepatic failure.World journal of gastroenterology · 2009Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 5 institutions in 2 countries.
Funding
Abstract
backgroundLiver transplantation is the treatment of choice for many patients with fulminant hepatic failure (FHF). A major limitation of this treatment is the lack of available donors. An optimally functioning bio-artificial liver (BAL) device has the potential to provide critical hepatic support to patients with FHF. In this study, we examined the efficacy of combining interleukin-1 (IL-1) receptor blockade with the synthetic function of hepatocytes in a BAL device for the treatment of FHF. MATERIALS AND
methodsWe injected an adenoviral vector encoding human IL-1 receptor antagonist (AdIL-1Ra) into the liver of D-galactosamine (GalN) intoxicated rats via the portal vein. We also transfected primary rat hepatocytes and reversibly immortalized human hepatocytes (TTNT cells) with AdIL-1Ra, and incorporated these transfected hepatocytes into our flat-plate BAL device and evaluated their efficacy in our GalN-induced FHF rat model after 10 h of extracorporeal perfusion.
resultsRats injected with AdIL-1Ra showed significant reductions in the plasma levels of hepatic enzymes. Primary rat hepatocytes transfected with AdIL-1Ra secreted IL-1Ra without losing their original synthetic function. Incorporating these cells into the BAL device and testing in a GalN-induced FHF rat model resulted in significant reductions in plasma IL-6 levels and significantly improved animal survival. Incorporating the AdIL-1Ra transfected TTNT cells in the BAL device and testing in the GalN-induced FHF rat model resulted in significantly reduced plasma IL-6 levels, and a trend toward improved survival was seen.
conclusionHepatocytes producing IL-1Ra are a promising cell source for BAL devices in the treatment of GalN-induced FHF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.